Genmab — Maj 2015
-
Det er kan vi forvente i aften:
-
"You can expect four abstracts on dara data and a HuMax-TF-ADC abstract, one on HuMax-AXL-ADC and an abstract from Gilead on ofatumumab plus Idealisib. As communicated yesterday the abstract on the Phase 2 daratumumab monotherapy study will be released on May 30th and not tonight".
-
Det er Jan Van de Winkels svar i Q&A i dag.
-
Under svag volume, som vi alle ved, vi ikke kan regne for noget - stiger Genmab i US http://www.euroinvestor.dk/boerser/nasdaq-otc-foreign/genmab-a-s/15387631
-
Jeg er sq i live endnu
-
same potatos. kig efter ORR, CR etc.
-
faktisk en gammel JV anbefaling. Italiensk barolo... fra phillipson wine
-
den burde nok have ventet lidt længere før den blev åbnet, men har ikke fået investeret i en vinkælder endnu, det må Jan Winkel lige hjælpe mig med
-
http://www.marketwatch.com/story/the-stocks-to-own-for-the-biotech-buyout-frenzy-2015-05-12?page=1 lidt anbefalinger af biotech, og hvorfor opkøbene kommer til at fortsætte
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind